Inhibitors of types I and V phosphodiesterase: Elevation of cGMP as a therapeutic strategy

被引：22

作者：

Czarniecki, M ^{[1
]}

Ahn, HS ^{[1
]}

Sybertz, EJ ^{[1
]}

机构：

[1] SCHERING PLOUGH CORP, RES INST, KENILWORTH, NJ 07033 USA

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31 | 1996年 / 31卷

关键词：

D O I：

10.1016/S0065-7743(08)60446-7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：61 / 70

页数：10

共 52 条

[1]

ADACHI H, 1995, 68 ANN M JPN PHARM S

[2]

AHN HS, 1992, ADV SEC MESS PHOSPH, V25, P271

[3]

Bacon E. R., 1994, [No title captured], Patent No. [5294612 A, 5294612, US 5294612]

[4]

BALCON R, 1992, CIRCULATION, V86, P100

[5]

BEAVO JA, 1994, MOL PHARMACOL, V46, P399

BEAVO, JA .

[7]

BELL A, 1993, Patent No. 9307149

[8]

Bell A.S., 1993, European Patent, Patent No. [526004, 0526004]

[9]

Bell A. S., 1992, Pyrazolopyrimidinone antianginal agents, Eur. Pat. Appl, Patent No. [463756, 463756 A1]

BELTMAN, J ;

SONNENBURG, WK ;

BEAVO, JA .